Anti-Toll-like receptor 4 TLR4 Antibody Picoband®

Overview

Anti-Toll-like receptor 4 TLR4 Antibody Picoband® is an antibody targeting TLR4. Common applications include WB, IHC, Flow Cytometry, ELISA. Key specifications include host: Rabbit; clonality: Polyclonal; isotype: Rabbit IgG; reactivity: Human; observed MW: 80 kDa; calculated MW: 95680 MW.

Boster Bio Anti-Toll-like receptor 4 TLR4 Antibody catalog # PA1484. Tested in IHC, WB applications. This antibody reacts with Human. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.

Key elements and design rationale

• Target: TLR4 — Toll-like receptor 4
• Antibody format: Host: Rabbit; Clonality: Polyclonal; Isotype: Rabbit IgG
• Species reactivity: Human
• Molecular weight guidance: Observed: 80 kDa; Calculated: 95680 MW

Specificity note: No cross reactivity with other proteins.

Biological background

Protein function (datasheet): Cooperates with LY96 and CD14 to mediate the innate immune response to bacterial lipopolysaccharide (LPS). Acts via MYD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Also involved in LPS- independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni (2+). Responses triggered by Ni (2+) require non-conserved histidines and are, therefore, species- specific. In complex with TLR6, promotes sterile inflammation in monocytes/macrophages in response to oxidized low-density lipoprotein (oxLDL) or amyloid-beta 42. In this context, the initial signal is provided by oxLDL- or amyloid-beta 42-binding to CD36. This event induces the formation of a heterodimer of TLR4 and TLR6, which is rapidly internalized and triggers inflammatory response, leading to the NF-kappa-B-dependent production of CXCL1, CXCL2 and CCL9 cytokines, via MYD88 signaling pathway, and CCL5 cytokine, via TICAM1 signaling pathway, as well as IL1B secretion. .

Scientific background (datasheet): TLR4, Toll-like receptor 4, is a protein that in humans is encoded by the TLR4 gene. TLR 4 is a toll-like receptor. TLR4, the human homolog of Drosophila Toll, is a type I transmembrane protein with an extracellular domain consisting of a leucine-rich repeat region and an intracellular domain homologous to that of human interleukin-1 receptor. The TLR4 gene is mapped to chromosome 9q32-q33 by fluorescence in situ hybridization.It detects lipopolysaccharide from Gram-negative bacteria and is thus important in the activation of the innate immune system.The protein encoded by this gene is a member of the Toll-like receptor (TLR) family, which plays a fundamental role in pathogen recognition and activation of innate immunity. TLRs are highly conserved from Drosophila to humans and share structural and functional similarities. They recognize pathogen-associated molecular patterns (PAMPs) that are expressed on infectious agents, and mediate the production of cytokines necessary for the development of effective immunity.

Cellular localization (datasheet): Cell membrane; Single-pass type I membrane protein. Upon complex formation with CD36 and TLR6, internalized through dynamin-dependent endocytosis. .

Tissue details (datasheet): Highly expressed in placenta, spleen and peripheral blood leukocytes. Detected in monocytes, macrophages, dendritic cells and several types of T-cells.

Sequence similarities (datasheet): Belongs to the Toll-like receptor family.

Research relevance and current trends

• Commonly studied in contexts related to Adaptive Immunity,Atherosclerosis,Cardiovascular,Host-Virus Interaction,Immunoglobulins,Immunology,Innate Immunity,Interspecies Interaction,Macrophage/Inflammation,Microbiology,Receptors,TLR Signaling,Vascular Inflammation.
• Supports comparative expression analysis across conditions, genotypes, or treatments when paired with appropriate controls.
• Useful for confirming target presence and subcellular distribution using orthogonal readouts (e.g., microscopy vs. immunoblotting).

Common research applications

• Western blot (WB): Compare relative target abundance and apparent size/isoforms across samples; interpret bands in light of expected MW and potential PTMs.
• ELISA: Measure target abundance in compatible matrices using a standard-curve readout; ensure dilution linearity and appropriate controls.
• Immunohistochemistry (IHC): Assess tissue distribution and cell-type patterns; interpret staining with appropriate negative controls and antigen context.
• Flow cytometry: Quantify target-positive populations in single-cell suspensions; pair with viability and isotype/FMO controls conceptually.

Notes for experimental interpretation

• Consider isoforms, post-translational modifications, and processing that can shift apparent molecular weight or localization.
• Cross-reactivity (datasheet): No cross-reactivity with other proteins
• Use appropriate positive and negative controls (e.g., KO/KD, blocking peptide, or isotype controls) to support specificity interpretation.

As a polyclonal antibody, this reagent may recognize multiple epitopes on the target, which can improve detection robustness but may require careful specificity controls.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.